This activity will address knowledge and practice gaps related to insulin therapy for patients with diabetes. Clinicians will be instructed on current unmet needs for basal insulin therapy, the pharmacokinetic and pharmacodynamic profiles of currently available basal insulin products, and the safety and efficacy of ultralong-acting basal insulin and assess their role in the treatment of patients with type 2 diabetes.
- Discuss current unmet needs for basal insulin therapy.
- Outline the pharmacokinetic and pharmacodynamic profiles of currently available basal insulin products.
- Summarize the safety and efficacy of ultralong-acting basal insulin and assess their role in the treatment of patients with diabetes.
This CME initiative is designed for Endocrinologists and Endocrine Fellows and other clinicians who care for patients with type 2 diabetes.
Andrew Ahmann, MD, MS
Professor of Medicine
Director, Harold Schnitzer Diabetes Health Center
Oregon Health & Science University
Dr. Ahmann is a board certified endocrinologist with a special interest in the care of patients with diabetes. He is a Professor of Medicine at Oregon Health and Science University and has been the Director of the Harold Schnitzer Diabetes Health Center at OHSU since it opened in 2007 to provide state of the art care for children and adults with diabetes. Dr. Ahmann has served on regional and national committees developing and updating guidelines for the care of those with diabetes. Beyond patient care, he is active in medical education and research. His clinical research has addressed new therapies, new technologies and best practices for type 1 and type 2 diabetes. Dr. Ahmann is an active volunteer for causes that benefit those with diabetes, including the ADA, JDRF, and the Chris Dudley Basketball Camp for children with diabetes.
This activity was launched on November 14, 2016 and will expire on November 1, 2017.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
By reviewing the course content and successfully completing the pre-test, post-test and evaluation, physicians are entitled to receive a maximum of 1.0 AMA PRA Category 1 Credits™. Statement of credit will be available to print from your user history page.
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the pre-test and activity evaluation.
• Pass the post-test (3 of 4 correct).
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members’ relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
Dr. Ahmann has served on an Advisory Board for Lilly and Dexcom. Dr. Ahmann has performed contracted research for Sanofi, Novo Nordisk, Medtronic, Dexcom, and Lexicon
Dawn Smiley-Byrd, MD, MSCR, Adjunct Associate Professor of Medicine,
Emory University School of Medicine, Staff Endocrinologist, Northside Hospital,
Atlanta, GA provided external review for this activity.
Others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any commercial interests.
Program supported by an educational grant from Sanofi US.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.